Skip to content

Clinical trials

Completed Drug-Related Side Effects and Adverse Reactions trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Drug-Related Side Effects and Adverse Reactions Phase: Not applicable Status: Completed Clear all

74 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20033
20062
20071
20082
20103
20112
20128
20132
20145
20158
20163
20175
20187
20195
20205
20213
20225
20231
20242
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed74

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Brigham and Women's Hospital5
VA Office of Research and Development4
Assistance Publique - Hôpitaux de Paris2
Fondation Ophtalmologique Adolphe de Rothschild2
Genelex Corporation2
McGill University Health Centre/Research Institute of the McGill University Health Centre2
Peking University People's Hospital2
Swansea University2
University of Pittsburgh2
Cedars-Sinai Medical Center1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Drug-Related Side Effects and Adverse Reactions74
Acute Kidney Injury2
Chronic Disease2
Diabetes Mellitus2
Diabetes Mellitus, Type 22
Frailty2
Macular Degeneration2
Psychotic Disorders2
Schizophrenia2
Acquired Immunodeficiency Syndrome1

Trials

Showing 1 to 25 of 74. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.